基本信息 产品详情 公司简介 推荐产品
网站主页 PLX5622 (hemifumarate) 化合物 PLX5622 hemifumarate
  • 化合物 PLX5622 hemifumarate|T12505|TargetMol

化合物 PLX5622 hemifumarate|T12505|TargetMol

PLX5622 hemifumarate
11313 200mg 起订
上海 更新日期:2025-11-17

TargetMol中国(陶术生物)

VIP2年
联系人:邵小姐
手机:15002134094 拨打
邮箱:marketing@targetmol.cn

产品详情:

中文名称:
化合物 PLX5622 hemifumarate
英文名称:
PLX5622 hemifumarate
品牌:
TargetMol
产地:
美国
保存条件:
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
产品类别:
抑制剂
货号:
T12505

Product Introduction

Bioactivity

名称PLX5622 hemifumarate
描述PLX5622 hemifumarate is a highly selective, blood-brain barrier-permeable, and orally active CSF1R inhibitor with an IC50 of 0.016 μM and a Ki of 5.9 nM. It can be used to eliminate proliferating and specific microglia before and during disease progression and is applicable for inducing Alzheimer's disease models.
体外活性PLX5622 (1-20 μM; 3 days) hemifumarate effectively depletes microglia while not affecting oligodendrocytes or astrocytes in cerebellar slices. PLX5622 (4 μM; 3 days) hemifumarate leads to a 30-40% reduction in NG2+ or PDGFRα+ cells, increasing to 90-95% at 20 μM. No reduction of NG2+ or PDGFRα+ OPCs is observed in slices exposed to 1 μM or 2 μM PLX5622 despite robust (~95%) depletion of the microglial cells [3].
体内活性Pharmacodynamics of PLX5622 hemifumarate in preclinical studies PLX5622 (1200 ppm; chow; for 3 weeks or 3 days; adult C57/Bl6 wild type mice) hemifumarate causes around 80% of microglia lost after 3 days of treatment and a 99% microglia loss after 3 weeks of treatment. PLX5622 (adult C57/Bl6 wild type mice aged 3 months; diet for 3 weeks) reduces microglia in cortex, striatum, cerebellum and hippocampus [4]. PLX5622 (50 mg/kg; intraperitoneal injection; once (neonatal rat) or twice (adult rat) a day; for a total of 14 days) hemifumarate depletes microglia by 80-90% within 3 days of treatment, which increases to > 90% by 7 days. After 14 days of PLX5622 treatment, microglia is depleted by > 96% in both neonates and adults while preserving baseline astrocyte quantity. (A single daily injection of 0.65% PLX5622 suspended in 5% dimethyl sulfoxide and 20% Kolliphor RH40 in 0.01 M PBS is sufficient for neonatal microglia depletion, adult depletion requires injections twice daily) [5]. PLX5622 (formulated in AIN-76A standard chow at 1200 mg/kg; for 28 days) hemifumarate leads to reduction in microglia throughout the CNS in 14-month-old 5xfAD mice [6]. Pharmacokinetics of PLX5622 hemifumarate in preclinical species [4] Species IV PO (gavage) Dose (mg/kg) AUC 0-∞ (ng hr/mL) CL (mL/min/kg) Vss (L/kg) t 1/2 (hr) Dose (mg/kg) AUC 0-∞ (ng hr/mL) Cmax (ng/mL) F Mouse 1.92 15,500 2.1 0.34 2.6 45 215,000 26,300 59% Rat (male) 1.13 2,630 7.7 1.2 2.3 45 99,600 12,000 95% Rat (female) 1.13 5,110 3.7 1.0 3.9 45 181,000 15,600 89% Dog 1.00 6,230 3.0 2.3 15 45 96,500 3,630 34% Monkey 1.35 2,100 11 1.6 2.2 ND ND ND ND Preparation of gavage dosing suspensions for PLX5622 hemifumarate [4] PLX5622 hemifumarate is dissolved in DMSO at a concentration that is 20x the final dosing solution. The compound stock is protected from light. A fresh stock is made each week. The components of the diluent generally are prepared a day or more in advance because they take time to dissolve completely: a) 2% hydroxypropyl methyl cellulose (HPMC): 2.0 g powder was brought to 100 mL deionized water; b) 25% Polysorbate 80 (PS80): 25 g was brought to 100 mL deionized water. To make 100 mL diluent, add 25 mL of 2% HPMC stock (0.5% final) and 4 mL of 25% PS80 stock (1% final) to 71 mL deionized water to have final 100 mL. Final composition after mixing with compound: 0.5% HPMC, 1% PS80, 5% DMSO. On each dosing day, the compound stock is diluted 20-fold as follows: 19 volumes of diluent are measured into the tube, and 1 volume of the 20x compound/DMSO stock is added. The cap is closed and the content of the tube is mixed by inversion and placed in a sonicating water bath to make a uniform suspension.
存储条件Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
溶解度10% DMSO+40% PEG300+5% Tween-80+45% Saline : 4 mg/mL (8.82 mM), Sonication is recommeded.
DMSO : 100 mg/mL (220.53 mM), Sonication is recommended.
关键字PLX-5622 Hemifumarate | PLX-5622 hemifumarate | PLX5622 hemifumarate | PLX5622 Hemifumarate | PLX-5622 | PLX5622 | PLX 5622 Hemifumarate | PLX 5622 | CSF1R | cFms
相关产品Cerdulatinib hydrochloride | GW786034B | Sotuletinib | PLX647 | Masitinib | JNJ-6204 | GW2580 | c-Fms-IN-1 | c-Fms-IN-13 | Pexidartinib | PLX5622 | c-Fms-IN-3
PLX5622 hemifumarate|TargetMol

公司简介

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿,致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区,已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库,以及多种类型的生化试剂产品,包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等,此外,我们还建设有CADD(计算机辅助药物设计)研究中心、药理实验室、药化合成平台三大技术中心,全方位满足客户的定制需求。 凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持,我们将有效帮助您缩短研发周期,取得更成功的结果。

成立日期 (13年)
注册资本 589.8595万人民币
员工人数 100-500人
年营业额 ¥ 1亿以上
经营模式 贸易,工厂,试剂,定制,服务
主营行业 中间体,天然产物,生物化工,化学试剂,生物技术服务

化合物 PLX5622 hemifumarate相关厂家报价

  • PLX5622
  • PLX5622
  • 陕西缔都医药化工有限公司 VIP
  • 2025-08-25
  • 询价
  • PLX5622
  • PLX5622
  • 湖北成丰化工有限公司
  • 2025-11-27
  • 询价
内容声明
拨打电话 立即询价